Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| SEPN | PRESS-RELEASE | neutral | 4/10 | Septerna reported Q2 2026 financial results highlighting a net loss of $13.0M (EPS -$0.29) vs consensus of -$0.48, a 39. | Aug 10, 2026 |
| AIM | PRESS-RELEASE | bearish | 5/10 | AIM ImmunoTech reported Q2 2026 net loss of $(3.8M) or $(0.43) per share, a 258% miss vs consensus of $(0.12). The compa | Aug 10, 2026 |
| HRTX | PRESS-RELEASE | bearish | 7/10 | Heron Therapeutics reported Q2 2026 revenue of $37.7M (missed consensus of $42.2M by 10.7%) and GAAP EPS of -$0.03 (miss | Aug 10, 2026 |
| COGT | PRESS-RELEASE | neutral | 5/10 | Cogent Biosciences reported Q2 2026 net loss of $96.4 million (EPS $-0.60 vs consensus $-0.56, a 6.2% miss) as R&D and G | Aug 10, 2026 |
| NTHI | PRESS-RELEASE | mixed | 6/10 | NeOnc reported Q2 2026 EPS of -$0.58, well below the -$0.16 consensus, with net loss widening to $14.2M on higher R&D sp | Aug 10, 2026 |
| KPTI | PRESS-RELEASE | neutral | 1/10 | Karyopharm Therapeutics Inc. announced it will report its Q2 2026 results on August 13, 2026. | Aug 10, 2026 |
| AXSM | PRESS-RELEASE | mixed | 6/10 | Axsome reported Q2 2026 net product revenue of $218.4M (+46% YoY), beating the $221.8M consensus, but GAAP EPS of -$1.26 | Aug 10, 2026 |
| VERU | PRESS-RELEASE | bullish | 7/10 | Veru reported fiscal Q3 2026 results with a net loss of -$0.30 per share, beating the -$0.32 consensus by 6.3%. The key | Aug 10, 2026 |
| TNXP | PRESS-RELEASE | mixed | 6/10 | Tonix Pharmaceuticals reported Q2 2026 net product revenue of $13.5M, up from $2.0M a year ago, driven by $11.0M in TONM | Aug 10, 2026 |
| JBIO | PRESS-RELEASE | bullish | 7/10 | Jade Biosciences reported Q2 2026 financial results with a net loss of $55.8M, wider than the $32.1M loss in Q2 2025, dr | Aug 10, 2026 |
| MLTX | PRESS-RELEASE | bullish | 7/10 | MoonLake reported Q2 2026 financials alongside positive Phase 3 IZAR-1 topline results for sonelokimab in psoriatic arth | Aug 10, 2026 |
| APGE | PRESS-RELEASE | bullish | 8/10 | Apogee Therapeutics reported Q2 2026 results but the quarter's significance is completely overshadowed by AbbVie's pendi | Aug 10, 2026 |
| ORKA | PRESS-RELEASE | bullish | 7/10 | Oruka Therapeutics reported Q2 2026 results in line with pre-revenue expectations: EPS of -$0.55 (consensus -$0.50) was | Aug 10, 2026 |
| GRFS | PRESS-RELEASE | neutral | 4/10 | Grifols announced completion of the clinical portion (last patient, last visit) of its Phase 3 SPARTA trial evaluating P | Aug 10, 2026 |
| TENX | PRESS-RELEASE | mixed | 7/10 | Tenax Therapeutics announced that its Phase 3 LEVEL trial of TNX-103 (oral levosimendan) in PH-HFpEF missed the primary | Aug 10, 2026 |
| GLSI | PRESS-RELEASE | bullish | 5/10 | Greenwich LifeSciences extended its insider and pre-IPO investor lock-up to January 31, 2027, preventing share sales dur | Aug 10, 2026 |
| OCS | PRESS-RELEASE | bullish | 5/10 | Oculis entered into an asset purchase agreement to fully acquire Accure Therapeutics' worldwide rights to Privosegtor (A | Aug 10, 2026 |
| ENTX | PRESS-RELEASE | mixed | 6/10 | Entera Bio reported Q2 2026 EPS of $-0.14, a 75% miss versus the $-0.08 consensus, though the company highlighted FDA al | Aug 7, 2026 |
| QNRX | PRESS-RELEASE | neutral | 1/10 | Quoin Pharmaceuticals, Inc. announced it will report its Q2 2026 results on August 14, 2026. | Aug 7, 2026 |
| ATOS | PRESS-RELEASE | neutral | 4/10 | Atossa Therapeutics reported Q2 2026 net loss of $8.5M ($0.95 per share), beating consensus of $1.04 loss per share by 8 | Aug 7, 2026 |
| HUMA | PRESS-RELEASE | neutral | 1/10 | Humacyte, Inc announced it will report its Q2 2026 results on August 12, 2026. | Aug 7, 2026 |
| BLSM | PRESS-RELEASE | bullish | 6/10 | BlossomHill Therapeutics priced its upsized IPO of 9,375,000 shares at $16.00/share, raising $150.0 million in gross pro | Aug 6, 2026 |
| LTGO | PRESS-RELEASE | neutral | 4/10 | Latigo Biotherapeutics priced its upsized IPO of 19,200,000 shares at $18.00 per share, raising $345.6 million in gross | Aug 6, 2026 |
| BIIB | PRESS-RELEASE | neutral | 4/10 | Biogen acquired RayThera Inc., a private immunology biotech, adding a Phase 1 small-molecule program and pipeline assets | Aug 6, 2026 |
| CLLS | PRESS-RELEASE | mixed | 5/10 | Cellectis reported Q2 2026 EPS of -$0.18, beating consensus of -$0.26 by 31.6%, but revenue of $5.2M missed estimates of | Aug 6, 2026 |
| INKT | PRESS-RELEASE | bullish | 6/10 | MiNK Therapeutics presented initial Phase 2 data at MHSRS showing first patients treated with agenT-797 for severe hypox | Aug 6, 2026 |
| CGON | PRESS-RELEASE | bearish | 7/10 | CG Oncology reported Q2 2026 EPS of -$0.90, significantly wider than the consensus estimate of -$0.64 (a 40.6% miss), wi | Aug 6, 2026 |
| DARE | PRESS-RELEASE | neutral | 1/10 | Daré Bioscience, Inc. announced it will host a conference call on August 13, 2026 to discuss its Q2 2026 results. | Aug 6, 2026 |
| CMPX | PRESS-RELEASE | bullish | 7/10 | Compass Therapeutics reported Q2 2026 net loss of $25.2M ($0.13/share), wider than the $19.9M loss in Q2 2025, driven by | Aug 6, 2026 |
| LXRX | PRESS-RELEASE | neutral | 5/10 | Lexicon Pharmaceuticals reported Q2 2026 revenue of $0.7M, down 97.6% from $28.9M a year ago due to the absence of a $27 | Aug 6, 2026 |